BGLC | BioNexus Gene Lab Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4000 - 0.4644
52 Week Range	0.3100 - 3.39
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	942,498
Average Volume	365,109
Shares Outstanding	17,967,700
Market Cap	7,977,659
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2021-01-08

Valuation
Profitability
Growth
Health
P/E Ratio	-2.96
Forward P/E Ratio	N/A
EPS	-0.15
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	30
Country	Malaysia
Website	BGLC

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

BGLC's peers: GLGI, IOSP, CBNT, FUL, PRM, AVOA, APGMF, ALTO, GEVO, GVDNY, OEC, NNOMF, SNES, LOOP, CRKN, GEVI, CMT, BCPC, NEU

*Chart delayed

Analyzing fundamentals for BGLC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see BGLC Fundamentals page.

Watching at BGLC technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BGLC Technicals page.